Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin

S. Casati, C. Castelnovo, M. Campise, C. Ponticelli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed 1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided into two groups. Group A comprised five patients with a greater mean aluminium (204 ± 28 μg/l) than the four patients in group B. Group A was given a mean dose of 25.8 g (range 14-39 g) of DFO over 6 months. Group B (aluminium values 112 ± 36 μg/l) was never treated with DFO. During the period of observation, plasma iron, serum ferritin and transferrin, as well as iron supplementation, did not differ between the groups. After DFO treatment a second DFO load test was performed. The mean predialysis aluminium value was significantly reduced in group A (204 ± 28 vs 111 ± 72 μg/l; P <0.05), while remaining unchanged in group B (112 ± 36 vs 140 ± 39 μg/l; P = ns). In both groups, the doses of rHuEpo necessary to maintain the same haemoglobin values decreased with time, but reduced significantly only in group A (298 ± 105 vs 110 ± 61 μg/kg per week; Δ -63%; P <0.01). Thus, aluminium interferes with the response to rHuEpo in haemodialysis patients, and the correction of aluminium overload with DFO can allow a considerable sparing of rHuEpo.

Original languageEnglish
Pages (from-to)441-443
Number of pages3
JournalNephrology Dialysis Transplantation
Volume5
Issue number6
Publication statusPublished - 1990

Fingerprint

Deferoxamine
Erythropoietin
Aluminum
Renal Dialysis
Therapeutics
Iron
Transferrin
Ferritins
Hemoglobins
Body Weight
Observation
Serum

Keywords

  • aluminium
  • anaemia
  • desferrioxamine
  • haemodialysis
  • recombinant human erythropoietin, rHuEpo

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin. / Casati, S.; Castelnovo, C.; Campise, M.; Ponticelli, C.

In: Nephrology Dialysis Transplantation, Vol. 5, No. 6, 1990, p. 441-443.

Research output: Contribution to journalArticle

Casati, S, Castelnovo, C, Campise, M & Ponticelli, C 1990, 'Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin', Nephrology Dialysis Transplantation, vol. 5, no. 6, pp. 441-443.
Casati, S. ; Castelnovo, C. ; Campise, M. ; Ponticelli, C. / Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin. In: Nephrology Dialysis Transplantation. 1990 ; Vol. 5, No. 6. pp. 441-443.
@article{83bae674349246d4934015622dfbdfff,
title = "Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin",
abstract = "In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed 1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided into two groups. Group A comprised five patients with a greater mean aluminium (204 ± 28 μg/l) than the four patients in group B. Group A was given a mean dose of 25.8 g (range 14-39 g) of DFO over 6 months. Group B (aluminium values 112 ± 36 μg/l) was never treated with DFO. During the period of observation, plasma iron, serum ferritin and transferrin, as well as iron supplementation, did not differ between the groups. After DFO treatment a second DFO load test was performed. The mean predialysis aluminium value was significantly reduced in group A (204 ± 28 vs 111 ± 72 μg/l; P <0.05), while remaining unchanged in group B (112 ± 36 vs 140 ± 39 μg/l; P = ns). In both groups, the doses of rHuEpo necessary to maintain the same haemoglobin values decreased with time, but reduced significantly only in group A (298 ± 105 vs 110 ± 61 μg/kg per week; Δ -63{\%}; P <0.01). Thus, aluminium interferes with the response to rHuEpo in haemodialysis patients, and the correction of aluminium overload with DFO can allow a considerable sparing of rHuEpo.",
keywords = "aluminium, anaemia, desferrioxamine, haemodialysis, recombinant human erythropoietin, rHuEpo",
author = "S. Casati and C. Castelnovo and M. Campise and C. Ponticelli",
year = "1990",
language = "English",
volume = "5",
pages = "441--443",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin

AU - Casati, S.

AU - Castelnovo, C.

AU - Campise, M.

AU - Ponticelli, C.

PY - 1990

Y1 - 1990

N2 - In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed 1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided into two groups. Group A comprised five patients with a greater mean aluminium (204 ± 28 μg/l) than the four patients in group B. Group A was given a mean dose of 25.8 g (range 14-39 g) of DFO over 6 months. Group B (aluminium values 112 ± 36 μg/l) was never treated with DFO. During the period of observation, plasma iron, serum ferritin and transferrin, as well as iron supplementation, did not differ between the groups. After DFO treatment a second DFO load test was performed. The mean predialysis aluminium value was significantly reduced in group A (204 ± 28 vs 111 ± 72 μg/l; P <0.05), while remaining unchanged in group B (112 ± 36 vs 140 ± 39 μg/l; P = ns). In both groups, the doses of rHuEpo necessary to maintain the same haemoglobin values decreased with time, but reduced significantly only in group A (298 ± 105 vs 110 ± 61 μg/kg per week; Δ -63%; P <0.01). Thus, aluminium interferes with the response to rHuEpo in haemodialysis patients, and the correction of aluminium overload with DFO can allow a considerable sparing of rHuEpo.

AB - In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed 1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided into two groups. Group A comprised five patients with a greater mean aluminium (204 ± 28 μg/l) than the four patients in group B. Group A was given a mean dose of 25.8 g (range 14-39 g) of DFO over 6 months. Group B (aluminium values 112 ± 36 μg/l) was never treated with DFO. During the period of observation, plasma iron, serum ferritin and transferrin, as well as iron supplementation, did not differ between the groups. After DFO treatment a second DFO load test was performed. The mean predialysis aluminium value was significantly reduced in group A (204 ± 28 vs 111 ± 72 μg/l; P <0.05), while remaining unchanged in group B (112 ± 36 vs 140 ± 39 μg/l; P = ns). In both groups, the doses of rHuEpo necessary to maintain the same haemoglobin values decreased with time, but reduced significantly only in group A (298 ± 105 vs 110 ± 61 μg/kg per week; Δ -63%; P <0.01). Thus, aluminium interferes with the response to rHuEpo in haemodialysis patients, and the correction of aluminium overload with DFO can allow a considerable sparing of rHuEpo.

KW - aluminium

KW - anaemia

KW - desferrioxamine

KW - haemodialysis

KW - recombinant human erythropoietin, rHuEpo

UR - http://www.scopus.com/inward/record.url?scp=0025354482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025354482&partnerID=8YFLogxK

M3 - Article

C2 - 2122321

AN - SCOPUS:0025354482

VL - 5

SP - 441

EP - 443

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 6

ER -